Stephen Letrent

Stephen (Steve) Letrent has a diverse work experience in the biotech and pharmaceutical industries. Currently, they serve as the Chief Development Officer and previously the Head of Clinical Development at TORL BioTherapeutics LLC, where they have been responsible for the development of novel antibody-based therapeutics for cancer patients. Prior to this, they were the Head of Development at 1200 Pharma. Stephen has also held senior leadership positions at Kyowa Kirin International PLC, Pfizer, and Bristol-Myers Squibb, where they played key roles in clinical development and strategy. Additionally, they have a background in clinical pharmacy, having worked as a Clinical Pharmacist at Thomas Jefferson University Hospitals. Stephen is currently a member of the Scientific Advisory Board at Talus Bio. Overall, Stephen Letrent has extensive experience in the development of therapeutics for cancer treatment and has made valuable contributions to the field throughout their career.

Stephen (Steve) Letrent holds a Ph.D. from the University of North Carolina at Chapel Hill, a Pharm.D. from the University of the Sciences in Philadelphia, and a B.S. from Duquesne University.